

Use of a PBPK modelling approach to predict the *in vivo* clearance of aldehyde oxidase substrates

Maily De Sousa Mendes^{1*}, Alexandra Orton², Helen E. Humphries¹, Barry Jones², Iain Gardner¹, Sibylle Neuhoff¹ and Venkatesh Pilla Reddy²

¹Simcyp (a Certara company), Sheffield, UK, ²AstraZeneca UK limited, Cambridge, UK

Background

Understanding **Aldehyde oxidase (AO)** clearance of compounds has become increasingly important in many drug discovery projects as compounds with less propensity for metabolism and interaction of CYP isozymes are being synthesised. However the less extensive knowledge about AO activity and abundance has led to **poor prediction of *in vivo* clearance (CL)** and consequently to clinical failure of some AO substrates [1,2].

In this work we aimed to assess the prediction of intravenous (IV) clearance of six AO substrates from *in vitro* data.

Methods

The involvement of AO in the metabolism of **O6-benzylguanine, BIBX1382, carbazeran, zaleplon, zonisporide and ziprasidone** was investigated.

AO activity was measured in human liver cytosol (HLC) (from Corning Life Sciences, Ultrapool of 150 donors) using 1mg/ml of final matrix concentration. After a pre-incubation period of 5 min at 37°C experiments were initiated by addition of test compound with a final concentration of 0.1 µM. HLC were incubated for 2 hours with sampling time at 0, 10, 30, 60, 90 and 120 min.




Fig. 1 : *In vitro-in vivo* extrapolation for scaling cytosolic metabolism

The IVIVE scaling approach uses the **well-stirred liver model** with a simulated average cytosolic protein per gram of liver (CPPGL) yield of 76.97 mg/g and a liver weight of 1570 g (Fig.1).

The **blood-to-plasma ratio (B:P)**, fraction unbound (**fu**) in plasma and in microsomes (**fu_{mic}**) were also measured and used to develop **physiologically based pharmacokinetic (PBPK) models** for each compound. Physicochemical properties were gathered and minimal PBPK models with a predicted volume of distribution from the Rodgers and Rowlands method were used [3].

The contribution of **microsomal metabolism, renal and biliary excretion** to clearance was added to the PBPK models when applicable.

All simulations were performed using **Simcyp V16R1** and the healthy volunteer population with an age range of 30-50 years and a proportion of 50% female.

The CL_{IV} were also predicted with CL_{int,AO} values obtained from the literature.

Finally the AO scaling approach was verified by comparing the predicted to observed CL_{IV}.

Results

Using newly generated *in vitro* data the average **CL_{IV} fold difference was 4.1** and ranged from 1.6 to 6.2 (Fig. 2). The best prediction were obtained for BIBX1382 (1.6 fold) and the biggest difference for zaleplon (6.2 fold). Assuming an fu_{mic} of 1 the average CL_{IV} fold difference was increased to 5.2 with a range from 2.1 to 8.6.




Fig. 2 : Predicted CL_{IV} of 6 AO substrates scaled from in house data

Results (con't)

The predicted fraction metabolised by AO were ranked as followed carbazeran > BIBX1382 > O6-benzylguanine > zaleplon > zonisporide > ziprasidone. There was no correlation between the fraction metabolised (fm) by AO and the underprediction of CL (Fig. 3).




Fig. 3 : Impact of fm AO on the fold prediction in CL_{IV}

An **average fold difference of 2.9** (range: 1.5-4.4) was obtained with literature CL_{int,AO} (Fig. 4).




Fig. 4 : Predicted CL_{IV} of 6 AO substrates scaled from literature data

The average *in vitro* intrinsic clearances obtained from the literature were higher and gave better CL_{IV} prediction. It could be explained by different activity in AO in the different human liver cytosolic fractions, or to the difference in the experiment (i.e. incubation and sampling time).

Conclusions and discussion

Overall, using HLC, the intravenous CL was under estimated by up to 6 fold, although an improved predictability was observed in comparison to the 5- to 40- fold lower IV clearance reported by Zientek *et al.* 2010 [4].

Potential reason for underprediction of clearance:

- *In vitro* assays: non optimal assay conditions, i.e issue with AO stability
- Limited clinical data for AO substrates with an fm >0.8
- Lack of robust information for other elimination routes
- **Extrahepatic metabolism in kidney and Lung** [5,6]. For these tissues, only relative expression are currently available, however for IVIVE the absolute abundance and it's scaling to **activity of the enzyme is needed**.

References

1. Fan PW, Zhang D, Halladay JS, Driscoll JP, Khojasteh SC. Going Beyond Common Drug Metabolizing Enzymes: Case Studies of Biotransformation Involving Aldehyde Oxidase, γ-Glutamyl Transpeptidase, Cathepsin B, Flavin-Containing Monooxygenase, and ADP-Ribosyltransferase. *Drug Metab Dispos.* 2016;44(8):1253–61.
2. Jensen KG, Jacobsen A-M, Bundgaard C, Nilausen DØ, Thale Z, Chandrasena G, Jørgensen M. Lack of Exposure in a First-in-Man Study Due to Aldehyde Oxidase Metabolism: Investigated by Use of 14C-microdose, Humanized Mice, Monkey Pharmacokinetics, and In Vitro Methods. *Drug Metab Dispos.* 2017;45(1):68–75.
3. Rodgers T, Rowland M. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. *J Pharm Sci.* 2006 Jun;95(6):1238–57
4. Zientek M, Jiang Y, Youdim K, Obach RS. In vitro-in vivo correlation for intrinsic clearance for drugs metabolized by human aldehyde oxidase. *Drug Metab Dispos.* 2010;38(8):1322–7.
5. Nishimura M, Naito S. Tissue-specific mRNA expression profiles of human phase I metabolizing enzymes except for cytochrome P450 and phase II metabolizing enzymes. *Drug Metab Pharmacokin.* 2006;21(5):357–74.
6. Moriwaki Y, Yamamoto T, Takahashi S, Tsutsumi Z, Hada T. Widespread cellular distribution of aldehyde oxidase in human tissues found by immunohistochemistry staining. *Histol Histopathol.* 2001;16(3):745–53.